By what mechanism does fingolimod cause macular edema?

Direct toxicity to retinal pigment epithelium

Vitreomacular traction from vitreous syneresis

Choroidal neovascularization under the fovea

In the FREEDOMS and TRANSFORMS trials, how often did fingolimod macular edema occur at the approved 0.5 mg dose?

Under 1 percent Macular edema occurred in under 1 percent at 0.5 mg and more often at 1.25 mg, so the absolute risk at the approved dose is low.

Which patients starting fingolimod need closer monitoring and a baseline OCT?

Patients with diabetes or prior uveitis Diabetes mellitus, a history of uveitis, higher doses and possibly older age raise the risk, so these patients need closer monitoring with baseline OCT.

Patients with prior optic neuritis

What is the standard ophthalmic screening schedule for patients starting fingolimod?

Baseline, then repeat at three to four months Examine the fundus and macula before treatment and again three to four months after starting, plus at any time vision changes, because edema usually appears in the first three to four months.

Annual examination after the first year

Examination only if vision changes

What does OCT typically show in fingolimod macular edema?

Subretinal fluid over a pigment epithelial detachment

Outer retinal atrophy with ellipsoid zone loss

An epiretinal membrane with retinal folds

In a patient with multiple sclerosis on fingolimod, which condition must be excluded before blaming the drug for macular edema?

Pars planitis Pars planitis is more frequent in multiple sclerosis and can cause macular edema, so the vitreous and peripheral retina should be examined before attributing edema to fingolimod.

Central serous chorioretinopathy

Why is OCT useful when a patient with multiple sclerosis on fingolimod reports blurred vision?

It helps separate macular edema from optic neuritis Optic neuritis also occurs in multiple sclerosis, and OCT helps distinguish it from fingolimod macular edema.

It measures intraocular pressure indirectly

It grades lens opacity objectively

It confirms fingolimod blood levels

What is the first step in managing fingolimod macular edema?

Stop the drug and discuss alternatives with the neurologist The drug is stopped and alternatives discussed with the neurologist; topical steroids or nonsteroidal drops may speed recovery in persistent cases.

Inject intravitreal anti-VEGF at once

What is the usual outcome after fingolimod is stopped for macular edema?

Resolution within weeks to months Most patients recover within weeks to months of stopping the drug, although a few have residual macular thinning.

Permanent central scotoma in most eyes

Edema persisting for several years

How should screening be handled for patients on siponimod, ozanimod or ponesimod?

Apply the same macular edema screening as fingolimod These newer S1P modulators act on the same pathway and their labels warn of macular edema, so the same screening principles apply to the whole class.

Screening only after five years

Fingolimod Macular Edema: Risk and Screening

Fingolimod macular edema is a dose-related complication of an oral drug for relapsing multiple sclerosis.

It usually appears within the first three to four months and often responds to stopping the drug.

Therefore, a baseline and an early follow-up examination form the core of safe prescribing.

How Fingolimod Macular Edema Occurs

Fingolimod binds sphingosine-1-phosphate receptors, which also sit on vascular endothelial cells.

Also, receptor modulation may increase vascular permeability in the macula.

As a result, fluid accumulates in the retina, and vision blurs.

Jain and Bhatti reviewed the evidence and described a typical onset in the first months.

Incidence of Fingolimod Macular Edema

In the phase 3 trials, FREEDOMS and TRANSFORMS, macular edema occurred in under 1 percent at 0.5 mg.

It was more frequent at the higher 1.25 mg dose.

Zarbin and colleagues reviewed the ophthalmic data from these studies.

Because 0.5 mg is the approved dose, the absolute risk is low.

Test your knowledge 10 questions from this article

Risk Factors for Fingolimod Macular Edema

Diabetes mellitus (see diabetic macular edema)
A history of uveitis (see uveitic macular edema)
Higher doses and, possibly, older age

Patients with these factors need closer monitoring and a baseline optical coherence tomography.

Screening for Fingolimod Macular Edema

Examine the fundus and the macula before starting treatment.

Then repeat the examination three to four months after the start.

Also examine at any time when vision changes.

Add optical coherence tomography for patients with diabetes or prior uveitis.

Symptoms and Signs of Fingolimod Macular Edema

Many patients have no symptoms, so screening catches cases early.

Others report blurred or distorted central vision.

Because optic neuritis also occurs in multiple sclerosis, OCT helps to separate the two (see demyelinating optic neuropathy).

Management of Fingolimod Macular Edema

Stop the drug and discuss alternatives with the neurologist.

Edema resolves in most patients within weeks to months.

Also, topical steroids or nonsteroidal drops may speed recovery in persistent cases.

Finally, avoid rechallenge unless the neurologic benefit is compelling and the eye is monitored.

Other Ocular Concerns on Fingolimod

Patients with multiple sclerosis also develop optic neuritis and intermediate uveitis.

Therefore, unexplained visual loss deserves a full examination and not an assumption about the drug.

Also, infections such as herpes zoster ophthalmicus occur more often on immunomodulating drugs.

Because the list is long, take a careful history.

Newer S1P Modulators

Siponimod, ozanimod, and ponesimod act on the same pathway.

Their labels also carry warnings about macular edema.

Also, patients who switch between agents keep their risk factors.

Therefore, apply the same screening principles to the whole class.

Fingolimod Macular Edema: Risk and Screening

Coordination With the Neurologist

Ask the neurologist to arrange the baseline examination before the first dose.

Then agree who performs the three-month review.

Also share the OCT results, since they help later decisions.

Because patients may see several clinicians, give them a written plan.

Patient Education

Tell patients to report blurred vision, distortion, or a dark spot promptly.

Also explain that the risk is low and treatable.

Because many do not notice early changes, stress the scheduled visits.

Pitfalls in Diagnosis

Edema in multiple sclerosis may come from pars planitis, which is more frequent in this disease.

Therefore, examine the vitreous and the peripheral retina before blaming the drug.

Also check the diabetic status and the blood pressure.

Key Points for the Clinician

Fingolimod macular edema is uncommon at the standard dose and usually reversible.

Also, a baseline and a three-month examination detect most cases.

Because diabetes and uveitis increase risk, monitor these patients more closely.

Imaging Findings

OCT shows intraretinal cysts in the central macula.

Also, the thickness map displays a rise in central subfield thickness.

Fluorescein angiography shows leakage in many cases, which separates it from nonleaking drug cysts.

Because both studies are widely available, use them together when the diagnosis is uncertain.

Special Situations

Pregnancy and breastfeeding affect the choice of drug, so coordinate with the neurologist.

Also consider patients with a single eye, since macular edema in that eye has a greater effect on daily life.

Therefore, monitor these patients with extra care.

Outcome After Stopping

Most patients recover vision within weeks to months of stopping the drug.

Also, a few have residual thinning of the macula.

Because early detection reduces the chance of lasting change, stick to the schedule.

References

Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78:672-680.
Zarbin MA, Jampol LM, Jager RD, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013;120:1432-1439.
Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-415.

Test yourself

A few questions straight from this article.

1 / 10 0 correct

By what mechanism does fingolimod cause macular edema?
Fingolimod binds sphingosine-1-phosphate receptors, which also sit on vascular endothelial cells; modulating them may increase macular vascular permeability so fluid accumulates.
In the FREEDOMS and TRANSFORMS trials, how often did fingolimod macular edema occur at the approved 0.5 mg dose?
Macular edema occurred in under 1 percent at 0.5 mg and more often at 1.25 mg, so the absolute risk at the approved dose is low.
Which patients starting fingolimod need closer monitoring and a baseline OCT?
Diabetes mellitus, a history of uveitis, higher doses and possibly older age raise the risk, so these patients need closer monitoring with baseline OCT.
What is the standard ophthalmic screening schedule for patients starting fingolimod?
Examine the fundus and macula before treatment and again three to four months after starting, plus at any time vision changes, because edema usually appears in the first three to four months.
What does OCT typically show in fingolimod macular edema?
OCT shows intraretinal cysts in the central macula, and the thickness map shows a rise in central subfield thickness.
In a patient with multiple sclerosis on fingolimod, which condition must be excluded before blaming the drug for macular edema?
Pars planitis is more frequent in multiple sclerosis and can cause macular edema, so the vitreous and peripheral retina should be examined before attributing edema to fingolimod.
Why is OCT useful when a patient with multiple sclerosis on fingolimod reports blurred vision?
Optic neuritis also occurs in multiple sclerosis, and OCT helps distinguish it from fingolimod macular edema.
What is the first step in managing fingolimod macular edema?
The drug is stopped and alternatives discussed with the neurologist; topical steroids or nonsteroidal drops may speed recovery in persistent cases.
What is the usual outcome after fingolimod is stopped for macular edema?
Most patients recover within weeks to months of stopping the drug, although a few have residual macular thinning.
How should screening be handled for patients on siponimod, ozanimod or ponesimod?
These newer S1P modulators act on the same pathway and their labels warn of macular edema, so the same screening principles apply to the whole class.

Ahmed Ophthalmologist

Writes and reviews the clinical articles on Educate. Every post is checked against peer-reviewed sources before it goes live.